Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine
Open Access
- 27 March 2019
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 37 (18), 2455-2462
- https://doi.org/10.1016/j.vaccine.2019.03.052
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013—RecommendationsVaccine, 2015
- Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trialHuman Vaccines & Immunotherapeutics, 2014
- Long-term Study of a Quadrivalent Human Papillomavirus VaccinePEDIATRICS, 2014
- Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine TrialCancer Prevention Research, 2013
- A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old GirlsPLOS ONE, 2013
- Understanding and learning from the success of prophylactic human papillomavirus vaccinesNature Reviews Microbiology, 2012
- Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance SerologyClinical and Vaccine Immunology, 2012
- A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus InfectionJournal of Virology, 2011
- Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 yearsHuman Vaccines, 2011
- Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine, 2007